Trials Annotator

Trial NCT02170025

View at ClinicalTrials.gov

Org. Study IDs: 17020
Secondary IDs: 2013-004595-35

Last trial update was posted on 2023-11-07

MeSH Interventions

Riociguat

MeSH Conditions

Cystic Fibrosis Fibrosis

Other Conditions

Stopping Reasons

Study was terminated after completion of Part 1, because Part 2 was no longer appropriate.

Limitations And Caveats

Based on multiple factors, the design of part 2 is no longer appropriate. Study was terminated at the end of part 1. No safety concerns were identified.

Result Publications

Derichs N, Taylor-Cousar JL, Davies JC, Fajac I, Tullis E, Nazareth D, Downey DG, Rosenbluth D, Malfroot A, Saunders C, Jensen R, Solomon GM, Vermeulen F, Kaiser A, Willmann S, Saleh S, Droebner K, Sandner P, Bear CE, Hoffmann A, Ratjen F, Rowe SM; Rio-CF Study Group. Riociguat for the treatment of Phe508del homozygous adults with cystic fibrosis. J Cyst Fibros. 2021 Nov;20(6):1018-1025. doi: 10.1016/j.jcf.2021.07.015. Epub 2021 Aug 19. [PMID: 34419414] [DOI: 10.1016/j.jcf.2021.07.015]

Annotations

Category Annotations

No annotators decided on categories yet

Intervention Annotations

#	Outdated	Intervention				Condition
#	Outdated	Name		Route	DrugBank ID	Condition